

Unither Pharmaceuticals, a global leader in sterile single dose technology, acquires Nanjing Ruinian Best Pharmaceutical - IEG as exclusive financial advisor to Unither & its main shareholder Ardian

- Unither Pharmaceuticals is one of France's leading pharmaceutical manufacturers
- With the acquisition, Unither aims to strengthen its position as the global leader in sterile single doses produced with Blow-Fill-Seal (BFS) technology
- IEG acted as exclusive financial advisor to Unither and its main shareholder Ardian

Paris | Nanjing, August 25th, 2020

Unither Pharmaceuticals, a global leader in sterile single dose technology, announced the acquisition of Nanjing Ruinian Best Pharmaceutical (NRB), a Chinese pharmaceutical company.

With the completion of this acquisition, Unither will further strengthen its position as the global leader in sterile single doses produced with Blow-Fill-Seal (BFS) technology and will support both Chinese and international pharmaceutical customers active in the ophthalmology and respiratory markets in China, and to offer them expertise in drug formulation and the manufacturing of sterile preservative-free single dose drugs.

In near term, Unither will focus on improving the quality, marketing, and development capabilities of NRB, to upgrade its current operational efficient and financial robustness. Then, Unither will expand production capacity by adding new B/F/S lines, production space and additional supply chain facilities to make it the hub for its China, and Asia access. For the long term, Unither aim to make this location a world class B/F/S manufacture for not only eye drops but also raspatory and other advanced pharmaceutical products.

IEG – Investment Banking Group has acted as exclusive financial advisor to Unither Pharmaceuticals and its main shareholder Ardian during this cross-border transaction.

About IEG – Investment Banking Group

IEG – Investment Banking Group is one of the leading, global independent investment banking boutiques focused on Mergers & Acquisitions, Financing & Principal Investments for the Internet, and Technology sector. Locally present in the key international growth regions and/or emerging markets, IEG – Investment Banking Group is a unique, influential, and trusted partner for growth companies and larger, international corporates. Founded in 1999, IEG has completed over 180 successful transactions to date with approximately 80 technology investment bankers. For further information about IEG – Investment Banking Group, please refer to: www.ieg-banking.com.

About Unither Pharmaceuticals

Unither Pharmaceuticals develops and manufactures pharmaceuticals products on behalf of its customers. Unither differentiates itself by specializing in certain pharmaceutical forms, sterile single unit dose, and by offering turnkey products to its customers, that they will be able to sell under their own brand. Unither, worldwide leader in single unit doses, is one of France's leading pharmaceutical manufacturers with a turnover of nearly € 300 million in 2018. The Group has four production plants in

France, one in the United States, one in Brazil and one development centre in Bordeaux. Its deep understanding of patient needs and its experience in product development and process implementation ensures the best conditions for our customers' market success. For more information about Unither Pharmaceuticals, please refer to: www.unither-pharma.com.

About NRB

NRB specializes in the development and production of solid and liquid form pharmaceutical products, with an annual revenue around EUR 10 million. It is based in Nanjing, Jiangsu Province, and has 130 employees. It is owned by Wuxi Jinyuan Industrial Investment Development Group Co. Ltd, an investment holding company located in Binhu district, in Wuxi. For more information about NRB, please refer to www.rnbt.com.